Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report released on Monday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 4.0 %

ORMP stock opened at $2.47 on Monday. Oramed Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $3.67. The company’s 50 day moving average is $2.36 and its two-hundred day moving average is $2.38. The stock has a market cap of $99.36 million, a P/E ratio of 22.41 and a beta of 1.77.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Murchinson Ltd. increased its holdings in shares of Oramed Pharmaceuticals by 0.5% in the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after acquiring an additional 8,889 shares during the period. XTX Topco Ltd increased its holdings in shares of Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 9,242 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares during the period. Virtu Financial LLC acquired a new position in shares of Oramed Pharmaceuticals in the 1st quarter valued at $68,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.